Randomized controlled clinical trial to compare the efficacy of Phalatrikadi Guggul with tablet Rosuvastatin in Medodushti with special reference to Nonalcoholic Fatty Liver Disease - NI

Dr Vijayalaxmi Sujay patil0 个研究点目标入组 0 人开始时间: 待定最近更新: 2024年8月19日

试验速览

暂无简介。

•1.Nonalcoholics, or history of alcohol intake less than 20gm/day (history of alcohol intake will taken separately obtained from the patient and close relatives).
•2.Clinical sign and symptoms suggesting NAFLD / Medodushti,i.e. pain in the Right upper quadrant/ epigastric region of the abdomen, feeling of nausea and vomiting, loss of appetite, burning sensation in the abdomen.
•3.No complaints – incidental finding during investigations for some other disease.
•4.Ultrasonography (USG) abdomen suggestive of NAFLD.
•5.Biochemical : Liver function tests showing raised alanine transaminases (ALT) or aspartate transaminases (AST) levels raised above the normal limits (40 IU/L up to 300 IU/L) and wiyh or without raised lipid profile.
•6.HbA1c < 9 gm/dl.
•7.BMI < 40.

•1.Patients with a H/O alcohol intake exceeding 20g/d (history of alcohol consumption history shall be separately obtained from the patient and close relatives)
•2.Patients testing positive for markers of other Viral Hepatitis.
•3.Pregnant women, Lactating mother.
•4.Patient suffering from Alcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis (NASH).
•5.Patients with complications of Nonalcoholic Fatty Liver Disease like Cardiovascular and Renal complications.
•6.Patients having Cholecystitis, Pancreatitis or any acute inflammatory condition.
•7.Patients having Uncontrolled DM (HbA1c > 9).
•8.Patients having major systemic illness like CA, Renal failure, HIV, IHD, Cirrhosis of Liver, Severe anaemia (Hb < 7gm%).
•9.BMI > 40
•10.Patients participating / participated in another clinical drug study within 3 months before recruitment.

发起方

Dr Vijayalaxmi Sujay patil